Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Amgen Inc NASDAQ: AMGN-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

More stories below advertisement

Latest Press Releases

Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
- PR Newswire - PRF - Mon Apr 19, 3:00PM CDT
PR Newswire - PRF - CMTX
Mon Apr 19, 3:00PM CDT
, /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor (FGFR2b) overexpressing and human epidermal growth factor receptor 2 (HER2)-negative metastatic and locally advanced gastric and gastroesophageal (GEJ) adenocarcinoma in combination with modified FOLFOX6 (fluoropyrimidine, leucovorin, and oxaliplatin), based on an FDA-approved companion diagnostic assay showing at least 10% of tumor cells overexpressing FGFR2b.
NeoGenomics Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients
- ACCESSWIRE - Mon Apr 19, 6:00AM CDT
ACCESSWIRE - CMTX
Mon Apr 19, 6:00AM CDT
SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type.
Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
- PR Newswire - PRF - Mon Apr 19, 6:00AM CDT
PR Newswire - PRF - CMTX
Mon Apr 19, 6:00AM CDT
, /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of , a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist, eligible patients may save on biomarker testing.
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
- PR Newswire - PRF - Fri Apr 16, 7:25AM CDT
PR Newswire - PRF - CMTX
Fri Apr 16, 7:25AM CDT
, /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately without giving effect to related transaction fees and expenses.
Extra Technology Named 2021 Digital Workforce Partner (EMEA) of the Year by Automation Anywhere
- CNW Group - Thu Apr 15, 12:19PM CDT
CNW Group - CMTX
Thu Apr 15, 12:19PM CDT
Extra Technology Named 2021 Digital Workforce Partner (EMEA) of the Year by Automation Anywhere
BioAge Signs Exclusive Agreement With Amgen To Develop and Commercialize Amgen's Phase 1 APJ Agonist To Treat Diseases of Aging
- BusinessWire - Wed Apr 14, 6:00AM CDT
BusinessWire - CMTX
Wed Apr 14, 6:00AM CDT
--The platform reveals that the apelin-APJ pathway preserves muscle function in older people and predicts future longevity
Datos Health Announces New Partnership For Study Measuring Impact Of Digital Solutions On Heart Failure Treatment
- PR Newswire - PRF - Tue Apr 13, 8:00AM CDT
PR Newswire - PRF - CMTX
Tue Apr 13, 8:00AM CDT
, /PRNewswire/ -- , a leader in remote care automation, today announced its collaboration with , one of the world's leading independent biotechnology companies, on a new study to evaluate the potential impact of digital health data to improve therapy in heart failure.
Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers
- BusinessWire - Sat Apr 10, 7:35AM CDT
BusinessWire - CMTX
Sat Apr 10, 7:35AM CDT
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, presents new data at the AACR Virtual Annual Meeting I, April 10-15, 2021, highlighting the use of the company's proprietary blood tests to advance precision oncology.
Global Biologic Therapeutic Drugs Market (2021 to 2025) - Featuring Amgen, Baxter and China Biologic Products Among Others
- GlobeNewswire - Fri Apr 2, 3:53AM CDT
GlobeNewswire - CMTX
Fri Apr 2, 3:53AM CDT
The "Biologic Therapeutic Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
Global Uveitis Drugs Market- AbbVie Inc., Alimera Sciences Inc., Amgen Inc., among others to contribute to the market growth|Industry Analysis, Market Trends, Market Growth, Opportunities and Forecast 2025
- PR Newswire - PRF - Thu Apr 1, 10:00PM CDT
PR Newswire - PRF - CMTX
Thu Apr 1, 10:00PM CDT
, /PRNewswire/ --

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies